K-Bio to showcase CDMO¡¤new drugs at the JP Morgan
By Son, Hyung Min | translator Hong, Ji Yeon
25.01.02 05:46:36
°¡³ª´Ù¶ó
0
'JP Morgan Healthcare Conference 2025' will be held in the US from January 13-16
Samsung Biologics¡¤Lotte Biologics¡¤Celltrion will seek potential partners¡¦ADC manufacturing plants have been secured
To explore potential out-licensing opportunities for a GLP-1 obesity drug¡¦Onconic¡¤Bridge Biotherapeutics will participate
The Korean pharmaceutical and biotech industry is set to participate in the new year's first global event, the JP Morgan Healthcare Conference. Attention has been drawn to what the Korean pharmaceutical and biotech industry will accomplish during the event, which will include discussions of blockbuster technology transfers and partnering agreements.
According to industry sources on January 2, Samsung Biologics, Lotte Biologics, Celltrion, Bridge Biotherapeutics, Onconic Therapeutics, and others will attend the JP Morgan Healthcare Conference. The Healthcare Conference, hosted by the US investment bank JP Morgan, is the largest pharmaceutical and biotech industry investment event, where venture
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)